Targeting adipose tissue in the treatment of obesity-associated diabetes

By C. Kusminski, P. Bickel, P. Scherer. Nature reviews. Drug discovery, 2016

640 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/7ce89ef085fc1cdf2c967ebab84e2546fc063e1b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Jamal Naderi
2. M. Longo
3. C. Miele
4. G. A. Raciti
5. F. Beguinot
6. Federica Zatterale

In Physiology

1. Jamal Naderi
2. M. Longo
3. C. Miele
4. G. A. Raciti
5. F. Beguinot
6. Federica Zatterale

Citations in the corpus

• The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. (2017, neutral): “Despite these results, the inhibition of angiogenesis as a therapeutic strategy for obesity remains a controversial notion (94).”
• Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments (2023, background): “Accordingly, different adipocytes induce different metabolic impacts on adiposity: the brown and beige adipocytes offer considerable benefits to energy homeostasis, whereas the altered white adipocytes in obesity are the culprit for multiple metabolic disorders (33).”
• Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications (2019, background): “The primary cause of T2D is obesity-driven insulin resistance (IR) in white adipose tissue (WAT), liver, and skeletal muscle, combined with impaired secretion of insulin by pancreatic β-cells to overcome this resistance [10].”